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ABSTRACT 
Program towards eradication of Poliomyelitis in developing countries is moving rapidly. Eradication of wild 
poliovirus jPom the Western Pacific region was achieved in October 2000. The key to poliomyelitis eradication in 
the world lies in the Indian subcontinent, and ifsuccess is achieved there, eradication elsewhere becomes a matter 
of time. However, the use of OPV is frequently followed by sporadic or even epidemic vaccine - associated polio. 
There are 2 excellent polio vaccines available. OPV has served us well, but the time has come to ask whether the 
risk of imported disease is greater or lesser then the sporadic and occasionally epidemic OPV associated 
poliomyelitis. The tradeoff seems to be between the safety ofIPV and the secondary gain in immunization afforded 
by the spread of OP V strains to contacts. Public Health circumstances are not static when wild poliovirus strains 
were circulating abundantly, if made good sense to abort that circulation rapidly by the application of OP V. The 
cases of VAPP could be seen as the price that had to be paid in order to keep polio at bay. Now, in 2003, we face a 
drfferent set of circumstances. Wild poliovirus no longer exist in the Western Pacific region and polio incidence is 
falling elsewhere. Therefore the substitution of IPV for OPV as has happened in North America and Europe, 
deserves new consideration for countries in this region including Malaysia. 
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INTRODUCTION 
Polio eradication program has shown significant 
progress since 1985. By year 2002, the number 
of endemic polio transmission countries declined 
to only 10 (Table 1) from about 20 in 2000. 
Rapid progress in poliovirus eradication owes its 
success largely to the widespread use of the oral 
poliovirus vaccine (OPV) developed by Albert 
Sabin. Eradication of wild poliovirus is possible 
because humans are the only hosts of human 
polioviruses, and because OPV has several major 
advantages. It is easily administered by mouth, 
which has facilitated the largest mass 
immunization campaign in history. OPV 
provides a long lasting high level of mucosal 
immunity, thus reducing transmissibility of wild 
polioviruses. The live attenuated poliovirus in 
OPV spreads to some contacts of vaccinee, 
increasing the impact of the vaccine beyond 
those actually vaccinated. Importantly, the 
elimination of wild polioviruses from much of 
the world is a testimony to the effectiveness of 
national and international public health 
programs. 
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Table 1 : Ten remaining endemic countries, 
highest to lowest transmission 
India 
Pakistan 
Nigeria 
Afghanistan 
Niger 
Somalia 
Egypt 
Angola 
Ethiopia 
Sudan 
The progressive elimination of wild poliovirus 
begun in 1963 in Cuba, the first country to 
implement a National Immunization Day (NID). 
This type of campaign led ultimately to the 
eradication of poliovirus from Americas in 1991 
and thereafter from European and Western 
Pacific region. 
OPV OUTBREAKS 
Unfortunately, there is a problematic side to 
reliance on OPV. This vaccine contains three 
attenuated strains of poliovirus, one for each of 
the major immunotypes (types 1, 2 and 3). Each 
attenuated strain of virus was derived by 
classical method of tissue culture pasSage and 
clonal selection for the attenuated phenotype. 
Detailed genetic analysis has revealed that the 
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attenuation was due to a small number of critical (Figure 1). A high proportion of immunized 
mutative points (1). After ingestion, OPV . subjects, perhaps 30% or more, excrete revertant 
replicates in the human intestine, with the straints of OPV, now called vaccine-derived 
generation of many mutants, some of which polioviruses (VDPVs) (2,3). VDPVs are highly 
exhibit revertant phenotypes, which may enterotropic and spread readily to non immune 
resemble the neurovirulence of wild polioviruses subjects. 
Sabin OPV Strains ATTENUATED 
GUT-GROWING 
CAPACITY 
Reversion to 
'enterovlrulence' 
rccomhr,rrr~ro,r. ,,r neurovirulence 
Neuropathogen~c~lyy Increased 
Trans~nissibiltty 
p- 
OUTBREAKS 
OPV = oral poliovirus vaccine; VAPP = vaccine-associated paralytic poliomyelitis. 
Adapted from Crainlc R. Benerits and risks of oral poliovirus vaccine. Presented at 
the 4"' ASIAN Expert Bureau on Pediatric Vaccines: Poliomyelitis - Surveillance 
and Vaccination. September 2001, Beij~ng. 
Figure 1: Mechanism Of Reversion of Sabin OPV Strains To Wild Poliovirus Phenotype 
At a population level, these characteristics have 
important complications. If close to 100% of a 
population is immunized, the vaccinees are 
exposed to the attenuated vaccine virus and 
developed immunity before revertant strains can 
cause paralysis. However, if immunization 
coverage is incomplete and a large proportion of 
the population does not participate, then a VDPV 
may spread sequentially through non immunized 
persons, accumulating mutations and reversions, 
which will increase the livelihood that 
someindividuals will develop paralytic 
poliomyelitis. In essence, a vaccine program 
might inadvertently initiate an outbreak of 
poliomyelitis, similar to natural outbreaks in the 
past. The circumstances favourable to such 
anoccurrence, particular low coverage and poor 
hygiene, have been reviewed and discussed 
extensively (4-6). The report by Ken et al. (7) 
provides a detailed documentation of just such an 
episode on the island of Hispaniola. The authors 
provide impressive evidence that a single type 1 
OPV virus underwent reversion and 
recombination with a wild enterovirus, and then 
spread to cause more than 20 virus-confirmed 
cases of paralytic poliomyelitis. Because there 
are usually 100 - 250 infections per paralytic 
case, it can be inferred that this virulent virus 
infected several thousand individuals. Most of 
the causes were documented in unvaccinated or 
incompletely vaccinated children under 15 years 
of age, where only about 30% of the population 
had received three doses of OPV. Thus the 
outbreak took place under exactly the conditions 
where it was postulated that OPV might spread 
(5). It is note worthy that at least two other 
similar small outbreaks have been observed, in 
Egypt and The Philippines, under similar 
circumstances (8,9). 
WILD POLIOVIRUS ERADICATION 
What are the implications of these observations 
for the poIiovirus eradication? Currently, in 
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countries where wild poliovirus has been 
eradicated like Malaysia, children are still being 
immunized with OPV. High immunization 
coverage is maintained to protect children 
against the possible reintroduction of wild 
poliovirus or exposure to VDPV. 
Progress towards eradication of poliomyelitis in 
developing countries is moving rapidly. 
Eradication of wild poliovirus from Western 
Pacific Region was achieved in October 2000. 
As has been marked by others, the key to 
poliomyelitis eradication lies in the Indian 
subcontinent, and if success is achieved there. 
eradication elsewhere becomes a matter of time. 
If we then take the optimistic view that soon the 
question of certifying world wide eradication of 
polio will pose itself, how will that be done if 
OPV vaccine remains in use? The prospect of 
searching for wild poliovirus in a sea of excreted 
Sabin strains, many of which will be 
recombinants (10), is daunting, particularly as 
that search will be conducted in 
asymptomatically infected living in developing 
countries.The risk of importation is real, as 
exemplified by a Canadian child of Indian origin 
who returned from India excreting wild 
poliovirus type I, although she herself was 
asymptomatic with respect to paralytic disease 
(1 1). No doubt many such importations into 
polio free counties take place each year without 
being detected, but the empirical evidence is that 
spread has not occurred except in unvaccinated 
communities. Moreover, as mentioned above, 
spread from the focus is blocked whether the 
larger population was vaccinated with IPV or 
with OPV. 
POLIO VACCINATION STRATEGIES 
Which strategies should a country choose in 
eradicating the disease. The Asian Expert Bureau 
on Pediatric Vaccines on September 2001 in 
Beijing, China agreed on a consensus statement 
as an accurate reflection of the principal 
opinions, issues and ideas debated:- 
OPV use is appropriate: 
In countries in which wild poliovirus 
has not yet been eradicated. 
And should be considered: 
0 To control any outbreak of 
poliomyelitis 
Sequential IPV-OPV use is acceptable in 
countries with: 
0 Certified eradication of wild poliovirus 
Adequate 3-dose DTP coverage rates 
(eg. at least 80%) 
0 A low risk of wild poliovirus 
importation, based on epidemiological 
assessments or eradication in the 
Southeast Asian region. 
To completely eliminate the risk of VAPP, an 
all-IPV schedule will be acceptable when the 
above conditions are met and 3-dose DTP 
coverage rates are 90% or greater, or after the 
global eradication of wild poliovirus. Table 2 
highlights the advantages and disadvantages of 
using all OPV, IPV-OPV (sequential) or all IPV 
schedule. 
Table 2: Poliomyelitis Vaccination Schedules: advantages and disadvantages 
All OPV IPV-OPV All-IPV 
Prevents wild-type paralytic Yes Yes Yes 
poliomyelitis 
Provides herd immunity Yes Yes Yes 
Induces intestinal immunity High High Moderate 
Provides contact immunity Yes Yes (some) No 
Approved for use in immunodeficient No  No No 
individuals 
Risk of VAPP Yes Some N o 
Other known serious adverse events None None None 
Heat sensitive Yes Yes (for OPV) No 
Requires extra injections No Not if Not if 
combination combination 
vaccine used vaccines used 
OPV = oral poliovirus vaccine; IPV = inactivated poliovirus vaccine; VAPP = vaccine-associated 
paralytic poliomyelitis 
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Polio Eradication Status And Vaccination paralytic poliomyelitis since 1986 when we had 1 
Strategy I n  Malaysia indigenous case. In 1992, there were 3 cases of 
paralytic poliomyeIitis which the wild polio virus 
Surveillance Background was believed to be imported from the lndian 
subcontinent (Figure 2). Together with the 
Where do Malaysia stand in this issue? Western Pacific region, Malaysia was declared 
Epidemiologically, we have been fiee fiom fiee fiom polio in October 2000. 
Year 
-
p
- 
Source : MOH 
Figure 2: Incidence of paralytic poliomyelitis in Malaysia 
Polio vaccines were available in Malaysia since 90% since 1991 (Figure 3). There were no cases 
1960s and it was incorporated into the National attributed to VAPP reported. However, 1 1.8% of 
Immunisation schedule in 1972. Iminunisation cases remained unclassifiable as non polio Acute 
coverage of polio vaccination has been more than Flaccid Paralysis (AFP). 
I 
i Number Of Cases 
i 
Coverage In X 
76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 ! 
Year 
Source : MOH ! 
-p-.....-.-----------ppp- ~ 
Figure 3: Reported Polio Cases and OPV3 Coverage - Malaysia 1976 - 1999 
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The incidence of  VAPP reported at the average of  There may be many reasons to  that and one o f  it 
1 : 750,000 (12) on the first dose world wide. may be due to inadequate stool specimens in the 
With a birth cohort of 550,000 per year, one AFP surveillance. W H O  targeted 80% of two 
would expect rhe occurrence of  VAPP to be one stool specimens within 2 weeks of  the onset of  
case per every 2 years. Why then have there been paralysis and what has been achieved in Malaysia 
no cases of VAPP reported in Malaysia? was between 50  - 60%. (Figure 4) 
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Figure  4: Percentage of stool specimen in A F P  Surveillance in Malaysia, 1997 - 2000 
VACCINATION S T R A T E G Y  ' F O R  
MALAYSIA 
Based on the epidemiological scenario and high 
immunisation coverage, I feel that it is high time 
for Malaysia to  review the current strategy of  
polio vaccination in the National Immunisation 
Program whereby Oral Polio Vaccine is used. To  
my opinion, the sequential IPV-OPV or all IPV 
schedule should be chosen soon in the future. 
There are two main concerns with regards to the 
implementation of  Inactivated Polio Vaccine in 
the National lmmunisation Schedule, they are (i) 
The reintroduction of  cases as  a result of  
importation of  wild viruses from the few 
remaining zones especially Indian subcontinent 
and (ii) The implication of cost. 
There have been many examples with regards to 
the herd immunity produced by IPV in countries 
that have implemented it - the IPV experience in 
Finland where a mass vaccination campaign has 
been conducted. Following this, poliomyelitis 
completely disappeared and did not return for a 
very long time despite the fact that scientist 
believe that poliovirus must have been re- 
imported back into the country countless times 
during this period. This experience shows that 
IPV induces very good serum immunity and also 
confers some protection against shedding, virus 
circulation and infection consequent of  re- 
introduction. Two doses of  IPV result in over 
98% seroconversion. If a booster is given later, 
very high antibody levels will be achieved. 
With regard to cost, although the cost of  IPV is 
higher than that of  OPV, the administration of  
IPV is more effective. The National Expanded 
Programme o f  lmmunisation (EPI) can be 
significantly improved especially since there is a 
combination vaccine with IPV available 
currently. The existing IPV combination vaccine 
that is registered in combination with DTP whole 
cell. In future, the combination with Acellular 
DTP and Hib is in the process of  registration. 
With mass production, the cost o f  adding IPV 
into combination vaccines becomes marginal. 
C O N C L U S I O N  
The choice of  which polio vaccine to choose, 
whether it is OPV or IPV or both, very much 
depends on factors like epidemiological status of 
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the disease, immunisation coverage and the risk 
level of importation. The 'end game' poses 
another dilemma that is not easily addressed. 'The 
ultimate goal of the eradication program is the 
discontinuation of all polio vaccination. 
Inevitably , an increasing number of people 
would become susceptible to these viruses. To 
ensure that poliovirus is not introduced into a 
susceptible population, it would be necessary to 
destroy or contain all stocks of these viruses that 
include fecal samples, collected for many 
different reasons and held in freezers, world 
wide, may be inadvertently contaminated with 
wild or vaccine derived polioviruses. 
Poliovirus eradication offer challenges to Public 
Health Specialists, Pediatricians and Health 
Policy Makers to come out with the best strategy 
that suits best to each country, region and hence 
the world. 
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